1260106-23-7

Usage

Molecular structure

1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-ene-1-carboxylic acid ethyl ester consists of a cyclohexene ring with a boron-containing substituent, an ester group, and a methyl group.

Functional groups

The compound contains a carboxylic acid group, an ethyl ester group, and a boronic acid functional group.

Reagent use

It is commonly used in organic synthesis as a reagent for the introduction of boronic acid functional groups.

Role in Suzuki-Miyaura cross-coupling reactions

The compound is often utilized in Suzuki-Miyaura cross-coupling reactions, which are widely used in the pharmaceutical and agrochemical industries.

Applications in industries

It is used in the synthesis of biaryl compounds, which are important for the development of new drugs and materials in the pharmaceutical and agrochemical industries.

Facilitation of carbon-carbon bond formation

The compound aids in the formation of carbon-carbon bonds, making it a valuable reagent in organic synthesis.

Intermediate in organic compound production

1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-ene-1-carboxylic acid ethyl ester serves as a valuable intermediate in the production of various organic compounds.

Upstream product

• 147905-77-9 ethyl 1-methyl-4-oxo-1-cyclohexanecarboxylate 
• 1257998-20-1 ethyl 1-methyl-4-(((trifluoromethyl)sulfonyl)oxy)cyclohex-3-enecarboxylate 
• 73183-34-3 bis(pinacol)diborane 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 24730-88-9 ethyl 8-methyl-1,4-dioxa-spiro[4.5]decane-8-carboxylate 

Downstream Products

• 1361144-68-4 ethyl 4-(7-(bis(2-(trimethylsilyl)ethoxy)methyl)aminopyrazolo[1,5-a]pyrimidin-5-yl)-1-methylcyclohex-3-enecarboxylate 
• 1361144-69-5 ethyl 4-(7-(bis(2-(trimethylsilyl)ethoxy)methyl)aminopyrazolo[1,5-a]pyrimidin-5-yl)-1-methylcyclohexanecarboxylate 
• 1361144-70-8 ethyl 4-(7-(bis((2(trimethylsilyl)ethoxy)methyl)amino)-3-iodopyrazolo[1,5-a]pyrimidin-5-yl)-1-methylcyclohexanecarboxylate 
• 1361144-71-9 ethyl 4-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-3-(6-fluoroquinolin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-1-methylcyclohexanecarboxylate 
• 1361144-72-0 ethyl 4-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-6-bromo-3-(6-fluoroquinolin-3-yl)pyrazolo[1,5-fl]pyrimidin-5-yl)-1-methylcycIohexanecarboxylate 
• 1361345-88-1 (Z)-ethyl 4-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-6-(2-ethoxyvinyl)-3-(6-fluoroquinolin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-1-methylcyclohexanecarboxylate 
• 1561949-72-1 [4-(ethoxycarbonyl)-4-methylcyclohex-1-en-1-yl]boronic acid 
• 1361450-11-4 ethyl 4-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-6-cyano-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-1-methylcyclohexanecarboxylate 
• 1361450-08-9 ethyl 4-(7-((bis(2-(trimethylsilyl)ethoxy)methyl)amino)-6-(1-ethoxyvinyl)-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-1-methylcyclohexanecarboxylate 
• 1361450-05-6 ethyl 4-(7-((bis(2-(trimethylsilyl)ethoxy)methyl)amino)-6-bromo-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-1-methylcyclohexanecarboxylate 
• 1361450-04-5 ethyl 4-(7-((bis(2-(trimethylsilyl)ethoxy)methyl)amino)-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-1-methylcyclohexanecarboxylate 
• 1361450-03-4 ethyl 4-(7-((bis(2-(trimethylsilyl)ethoxy)methyl)amino)-3-iodopyrazolo[1,5-a]pyrimidin-5-yl)-1-methylcyclohex-3-enecarboxylate 
• 1260106-24-8 ethyl 4-(7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-1-methylcyclohex-3-enecarboxylate 
• 1260105-77-8 1-methyl-4-(3-(6-phenylpyridin-3-yl)-8H-pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidin-5-yl)cyclohex-3-enecarboxylic acid 

Relevant academic research and scientific papers

MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE

The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

The present invention relates to compounds according to Formula I: and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

As a substituted bicyclic pyrazole compound and use ROR γ T inhibitor

The present invention relates to compounds according to Formula I: and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

SUBSTITUTED INDAZOLE COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF

The present invention relates to compounds according to Formula (I) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

3-CYCLOHEXENYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF

Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

NOVEL PYRAZOLO[1,5-a]PYRROLO[3,2-e]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS

The present invention relates to certain pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine compounds of Formula (I) as inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatm

NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS

The present invention relates to certain pyrazolo[1,5-a]pyrimidine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrimidine compounds.

FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS

The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R1, R2, R3, and R4 are as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders.